Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
5(56%)
Results Posted
67%(2 trials)

Phase Distribution

Ph phase_3
2
22%
Ph phase_1
1
11%
Ph phase_2
5
56%
Ph early_phase_1
1
11%

Phase Distribution

2

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
5(55.6%)
Phase 3Large-scale testing
2(22.2%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

5

trials recruiting

Total Trials

9

all time

Status Distribution
Active(5)
Completed(3)
Other(1)

Detailed Status

Active, not recruiting4
Completed3
Recruiting1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
5
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (11.1%)
Phase 11 (11.1%)
Phase 25 (55.6%)
Phase 32 (22.2%)

Trials by Status

recruiting111%
active_not_recruiting444%
unknown111%
completed333%

Recent Activity

5 active trials
Showing 5 of 9
active_not_recruitingphase_3

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694
active_not_recruitingphase_3

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

NCT03003962
recruitingphase_2

Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

NCT06680050
active_not_recruitingearly_phase_1

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

NCT03215095
active_not_recruitingphase_2

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

NCT03833440
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT03528694Phase 3

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

Active Not Recruiting
NCT03003962Phase 3

Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL)

Active Not Recruiting
NCT06680050Phase 2

Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen

Recruiting
NCT03215095Early Phase 1

RAI Plus Immunotherapy for Recurrent/Metastatic Thyroid Cancers

Active Not Recruiting
NCT03833440Phase 2

Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

Active Not Recruiting
NCT02793466Phase 1

Durvalumab in Pediatric and Adolescent Patients

Completed
NCT03853187Phase 2

Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer

Completed
NCT03101475Phase 2

Synergism of Immunomodulation and Tumor Ablation

Completed
NCT04293419Phase 2

Durvalumab (MEDI4736) Plus Total Neoadjuvant Therapy (TNT) in Locally Advanced Rectal Cancer

Unknown

All 9 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
9